Literature DB >> 20870345

Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.

Magali Sasso1, Michel Beaugrand, Victor de Ledinghen, Catherine Douvin, Patrick Marcellin, Raoul Poupon, Laurent Sandrin, Véronique Miette.   

Abstract

There is a need for noninvasive methods to detect liver steatosis, which can be a factor of liver fibrosis progression. This work aims to evaluate a novel ultrasonic controlled attenuation parameter (CAP) devised to target, specifically, liver steatosis using a sophisticated process based on vibration control transient elastography (VCTE™). CAP was first validated as an estimate of ultrasonic attenuation at 3.5 MHz using Field II simulations and tissue-mimicking phantoms. Performance of the CAP was then appraised on 115 patients, taking the histological grade of steatosis as reference. CAP was significantly correlated to steatosis (Spearman ρ = 0.81, p < 10(-16)). Area under receiver operative characteristic (ROC) curve (AUC) was equal to 0.91 and 0.95 for the detection of more than 10% and 33% of steatosis, respectively. Furthermore, results show that CAP can efficiently separate several steatosis grades. These promising results suggest that CAP is a noninvasive, immediate, objective and efficient method to detect and quantify steatosis.
Copyright © 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20870345     DOI: 10.1016/j.ultrasmedbio.2010.07.005

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  215 in total

Review 1.  Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan(®)).

Authors:  Monica Lupsor-Platon; Radu Badea
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

2.  Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Authors:  Wah-Kheong Chan; Nik Raihan Nik Mustapha; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Sanjiv Mahadeva
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

Review 3.  Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.

Authors:  Andrew H Talal; Charles S Venuto; Islam Younis
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

4.  Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference.

Authors:  Jing-Houng Wang; Hsin-You Ou; Yi-Hao Yen; Chien-Hung Chen; Sheng-Nan Lu
Journal:  Dig Dis Sci       Date:  2019-10-15       Impact factor: 3.199

5.  Prognostic Value of Controlled Attenuation Parameter by Transient Elastography.

Authors:  Ken Liu; Vincent Wai-Sun Wong; Keith Lau; Sienna Du Liu; Yee-Kit Tse; Terry Cheuk-Fung Yip; Raymond Kwok; Alex Yiu-Wa Chan; Henry Lik-Yuen Chan; Grace Lai-Hung Wong
Journal:  Am J Gastroenterol       Date:  2017-10-31       Impact factor: 10.864

Review 6.  Nonalcoholic fatty liver disease in Asia: emerging perspectives.

Authors:  Wai-Kay Seto; Man-Fung Yuen
Journal:  J Gastroenterol       Date:  2016-09-16       Impact factor: 7.527

7.  Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease.

Authors:  Ivana Mikolasevic; Lidija Orlic; Sandra Milic; Vesna Lukenda; Sanjin Racki; Davor Stimac; Ervin Avdovic; Luka Zaputovic
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

Review 8.  Invasive and non-invasive diagnosis of cirrhosis and portal hypertension.

Authors:  Moon Young Kim; Woo Kyoung Jeong; Soon Koo Baik
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

9.  Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults.

Authors:  Jennifer C Price; Jennifer L Dodge; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan Noworolski; Phyllis C Tien
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

Review 10.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.